Invivyd (NASDAQ:IVVD) Given "Buy" Rating at D. Boral Capital

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating reissued by D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Several other analysts have also recently weighed in on IVVD. Morgan Stanley dropped their price objective on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Invivyd in a report on Monday, February 24th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Invivyd has an average rating of "Buy" and a consensus target price of $7.89.

Invivyd Price Performance

NASDAQ IVVD traded down $0.01 during trading on Thursday, reaching $0.72. 2,515,692 shares of the company's stock were exchanged, compared to its average volume of 4,232,410. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $4.74. The stock has a market capitalization of $86.60 million, a P/E ratio of -0.37 and a beta of 0.09. The business has a 50 day moving average price of $0.98 and a 200-day moving average price of $0.87.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.10. The company had revenue of $13.80 million for the quarter, compared to the consensus estimate of $13.57 million. On average, analysts forecast that Invivyd will post -1.64 earnings per share for the current year.

Remove Ads

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 86,545 shares of the stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $0.48, for a total value of $41,541.60. Following the completion of the sale, the director now owns 3,170,231 shares of the company's stock, valued at approximately $1,521,710.88. This represents a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 17.90% of the stock is owned by corporate insiders.

Institutional Trading of Invivyd

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its position in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after acquiring an additional 87,358 shares during the last quarter. Barclays PLC grew its stake in Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after purchasing an additional 9,207 shares during the period. Renaissance Technologies LLC bought a new stake in Invivyd in the fourth quarter worth approximately $74,000. JPMorgan Chase & Co. lifted its position in shares of Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock valued at $114,000 after acquiring an additional 222,375 shares during the period. Finally, Two Sigma Advisers LP grew its stake in shares of Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock valued at $135,000 after buying an additional 282,100 shares during the period. Institutional investors and hedge funds own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.